Evolution of Primary Protease Inhibitor Resistance Mutations during Protease Inhibitor Salvage Therapy

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2002-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.46.4.1086-1092.2002PMID 11897594PMCID PMC127108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Resistance to protease inhibitors].

  2001cited by this paper
• Individual Contributions of Mutant Protease and Reverse Transcriptase to Viral Infectivity, Replication, and Protein Maturation of Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1

  2001cited by this paper
• High Degree of Interlaboratory Reproducibility of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Sequencing of Plasma Samples from Heavily Treated Patients

  2001cited by this paper
• Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.

  2001cited by this paper
• Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients

  2001cited by this paper
• International perspectives on antiretroviral resistance. Resistance to protease inhibitors.

  2001cited by this paper
• Computational and Evolutionary Analysis of HIV Molecular Sequences

  2001cited by this paper
• Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.

  2000cited by this paper
• Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

  2000cited by this paper
• Structural and Kinetic Analyses of the Protease from an Amprenavir-Resistant Human Immunodeficiency Virus Type 1 Mutant Rendered Resistant to Saquinavir and Resensitized to Amprenavir

  2000cited by this paper
• Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.

  2000cited by this paper
• Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients

  2000cited by this paper
• Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples

  2000cited by this paper
• HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed

  1999cited by this paper
• Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.

  1999cited by this paper
• Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.

  1999cited by this paper
• Phenotypic HIV-1 Resistance Correlates with Treatment Outcome of Nelfinavir Salvage Therapy

  1999cited by this paper
• Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.

  1999cited by this paper
• Constrained Evolution of Human Immunodeficiency Virus Type 1 Protease during Sequential Therapy with Two Distinct Protease Inhibitors

  1999cited by this paper
• Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy.

  1999cited by this paper
• Mutation Patterns of the Reverse Transcriptase and Protease Genes in Human Immunodeficiency Virus Type 1-Infected Patients Undergoing Combination Therapy: Survey of 787 Sequences

  1999cited by this paper
• Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1

  1999cited by this paper
• Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype.

  1999cited by this paper
• Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.

  1999cited by this paper
• Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients

  1998cited by this paper
• Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients

  1998cited by this paper
• Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

  1997cited by this paper
• Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions.

  1986cited by this paper

• Kinetic coevolutionary models predict the temporal emergence of HIV-1 resistance mutations under drug selection pressure

  2023cites this paper
• Crystallographic and enzyme kinetics studies of multidrug resistant HIV-1 protease mutants PR20 and PRS17

  2022cites this paper
• Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PRS17.

  2021cites this paper
• Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (Schizosaccharomyces pombe)

  2021cites this paper
• Highly Drug-Resistant HIV-1 Protease Mutant PRS17 Shows Enhanced Binding to Substrate Analogues

  2019cites this paper
• Development of A Fission Yeast Cell-based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.

  2019cites this paper
• Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.

  2019cites this paper
• Viral Proteases as Drug Targets and the Mechanisms of Drug Resistance: A Dissertation

  2016cites this paper
• Dynamical Network of HIV-1 Protease Mutants Reveals the Mechanism of Drug Resistance and Unhindered Activity.

  2016cites this paper
• Effects of Hinge-region Natural Polymorphisms on Human Immunodeficiency Virus-Type 1 Protease Structure, Dynamics, and Drug Pressure Evolution*

  2016cites this paper
• Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.

  2016cites this paper
• Recovery of the wild type atomic flexibility in the HIV-1 protease double mutants.

  2015cites this paper
• Substrate-Envelope-Guided Design of Drugs with a High Barrier to the Evolution of Resistance

  2015cites this paper
• HIV‐1 transmitted drug resistance and genetic diversity among patients from Piauí State, Northeast Brazil

  2015cites this paper
• The Role of Select Subtype Polymorphisms on HIV-1 Protease Conformational Sampling and Dynamics*

  2014cites this paper
• Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease

  2014cites this paper
• Defective Hydrophobic Sliding Mechanism and Active Site Expansion in HIV-1 Protease Drug Resistant Variant Gly48Thr/Leu89Met: Mechanisms for the Loss of Saquinavir Binding Potency

  2014cites this paper
• Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease.

  2013cites this paper
• Mechanism of HIV antiretroviral drugs progress toward drug resistance

  2012cites this paper
• Enhancing Protein Backbone Binding—A Fruitful Concept for Combating Drug‐Resistant HIV†

  2012cites this paper
• Verstärkung der Bindung an das Proteinrückgrat – ein fruchtbares Konzept gegen die Arzneimittelresistenz von HIV†

  2012cites this paper
• Resistant mechanism against nelfinavir of subtype C human immunodeficiency virus type 1 proteases

  2011cites this paper
• HIV Genetic Diversity and Drug Resistance

  2010cites this paper
• Analyse von virusspezifischen Resistenzfaktoren und phylogenetischer Entwicklung von Hepatitis B Viren unter Therapie mit Adefovir

  2010cites this paper
• Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation

  2009cites this paper
• Co-evolution of HIV-1 Protease and its Substrates: A Dissertation

  2009cites this paper
• Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance

  2009cites this paper
• Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742

  2008cites this paper
• [Resistance to darunavir].

  2008cites this paper
• Impact on Replicative Fitness of the G48E Substitution in the Protease of HIV-1: An In Vitro and In Silico Evaluation

  2008cites this paper
• Novel Method for Probing the Specificity Binding Profile of Ligands: Applications to HIV Protease

  2008cites this paper
• Antiretroviral Therapy in HIV-Infected Patients with Multidrug-Resistant Virus: Applying the Guidelines to Practice

  2008cites this paper
• Resistencias a darunavir

  2008cites this paper
• Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials

  2008cites this paper
• GRL-02031, a Novel Nonpeptidic Protease Inhibitor (PI) Containing a Stereochemically Defined Fused Cyclopentanyltetrahydrofuran Potent against Multi-PI-Resistant Human Immunodeficiency Virus Type 1 In Vitro

  2008cites this paper
• Viral Quasispecies: Dynamics, Interactions, and Pathogenesis

  2008cites this paper
• Estudio de carcterísticas fenotípicas del VIH mediante la generación y desarrollo de virus recombinantes: aplicación al estudio de la capacidad replicativa de virus multirresistentes

  2007cites this paper
• Antiretroviral (ARV) drug resistance in the developing world.

  2007cites this paper
• Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.

  2007cites this paper
• Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.

  2006cites this paper
• N88D Facilitates the Co-occurrence of D30N and L90M and the Development of Multidrug Resistance in HIV Type 1 Protease following Nelfinavir Treatment Failure

  2006cites this paper
• Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.

  2006cites this paper
• Rapid Propagation of Low-Fitness Drug-Resistant Mutants of Human Immunodeficiency Virus Type 1 by a Streptococcal Metabolite Sparsomycin

  2006cites this paper
• Structural and dynamical properties of different protonated states of mutant HIV-1 protease complexed with the saquinavir inhibitor studied by molecular dynamics simulations.

  2006cites this paper
• Procede de determination de la reduction de la receptivite du vih a un traitement inhibiteur de la protease

  2005cites this paper
• Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

  2005cites this paper
• Confronting the Emergence of Drug-Resistant HIV Type 1: Impact of Antiretroviral Therapy on Individual and Population Resistance

  2005cites this paper
• Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism.

  2005cites this paper
• Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.

  2005cites this paper
• Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.

  2004cites this paper
• Measurement of HIV RNA in patients infected by subtype C by assays optimized for subtype B results in an underestimation of the viral load

  2004cites this paper
• Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C

  2004cites this paper
• Mutation D30N Is Not Preferentially Selected by Human Immunodeficiency Virus Type 1 Subtype C in the Development of Resistance to Nelfinavir

  2004cites this paper
• Peptidomimetic inhibitors of HIV protease.

  2004cites this paper
• Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

  2003cites this paper
• Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response

  2003cites this paper
• I. Rationale for HIV-1 drug resistance testing II. Evolution of HIV-1 drug resistance III. Identifying and characterizing drug resistance mutations IV. Protease inhibitor (PI) resistance V Nucleoside/nucleotide RT inhibitor (NRTI) resistance VI Nonnucleoside RT inhibitor (NNRTI) resistance mutations

  2003cites this paper
• Interaction Characteristics of Viral Protease Targets and Inhibitors Perspectives for Drug Discovery and Development of Model Systems

  2003cites this paper
• Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation.

  2003cites this paper
• Dual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene

  2003cites this paper
• Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors

  2003cites this paper
• Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments

  2003cites this paper
• Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance

  2002cites this paper